Key result
Olaparib combined with 177Lu increased persistent double-strand breaks by a factor of 3.3 and showed higher radiosensitization efficacy in PC-3 cells than 223Ra or X-rays.
Why the study?
To determine whether combining a PARP inhibitor with different radiation qualities results in different levels of radiosensitization in PC-3 prostate cancer cells.
Does Olaparib combined with different radiation qualities increase radiosensitization in PC-3 prostate cancer cells?
Does Olaparib combined with different radiation qualities increase radiosensitization in PC-3 prostate cancer cells?
Answers are grounded in this paper and cite their sources.
Olaparib differentially sensitizes PC-3 prostate cancer cells to various radiation types, with the highest efficacy observed in combination with the beta-emitter 177Lu.
Background: New therapeutic strategies for metastatic castration-resistant prostate cancer (mCRPC) have been developed in the past to achieve the best response rates. Most recently, the use of combination therapies has been explored to optimize patient outcomes. Poly(ADP-ribose) polymerase inhibitors (PARPi) may help to treat mCRPC more effectively. Objectives: This study aimed to determine whether the combination of a PARPi with different radiation qualities results in different levels of radiosensitization of PC-3 cells. Methods: The radiosensitizing potential of Olaparib in combination with 177Lu, 223Ra, X-rays and photodynamic therapy (PDT) using the UVA light-activated photosensitizer ortho-iodoHoechst33258 (oIH) was evaluated by determining the clonogenic survival, DNA damage and cell cycle analysis. Results: Here, we show that this combination strategy differentially sensitized PC-3 cells to different radiation qualities. The combination of 177Lu with Olaparib increased the numbers of persistent double-strand breaks (DSBs) by a factor of 3.3 and cell death in PC-3 cells. Overall, the β-emitter 177Lu indicated a higher radiosensitization efficacy compared to 223Ra, with X-rays corresponding to dose modification factors (DMF) of 1.77, 1.17 and 1.16 respectively. Even in the case of the α-emitter 223Ra, the effects were much less pronounced than for 177Lu. PARPi also showed a slight potentiation of the cytotoxic effects both in co-treatment with X-rays and with PDT. Conclusions: The results of our study indicate a potential role for Olaparib in further optimizing the PSMA radioligand therapy (PRLT) outcomes. However, further evaluation of the combination of PARPi with PRLT is needed to gain more insights into improving the benefit to patients suffering from mCRPC.
No takes yet. Share an insight, caveat, or question.
Mass et al. (2024) studied Metastatic castration-resistant prostate cancer (mCRPC) cell model. Olaparib combined with 177Lu, 223Ra, X-rays, or photodynamic therapy vs. Radiation alone was evaluated on Radiosensitization (clonogenic survival, DNA damage, and cell cycle analysis). Olaparib combined with 177Lu increased persistent double-strand breaks by a factor of 3.3 and showed higher radiosensitization efficacy in PC-3 cells than 223Ra or X-rays.
Synapse has enriched 10 related papers. Consider them for comparative context: